Great advances in the systemic treatment in malignant melanoma patients : Stora framsteg för systemisk behandling vid malignt melanom.

• Great advances in the systemic treatment in malignant melanoma patients Up until a few years ago there was no systemic treatment with the capacity to prolong overall survival for patients with advanced malignant melanoma. Several new treatments have been established in clinical practice in recent years and they belong to two main groups; checkpoint inhibitors and inhibitors of an intracellular pathway (MAP kinase). The latter drugs are only active in melanomas with an activating BRAF mutation, which is present in half of the patients. Side effect management is important and in particular for the checkpoint inhibitors, which activate the immune system and frequently provoke immune related reactions. The introduction of these new treatments has substantially improved prognosis and some patients might even be cured. Based on ongoing research, more therapeutic breakthroughs can be anticipated in the years to come.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Antibodies

Monoclonal

adverse effects

economics

pharmacology

therapeutic use

Antineoplastic Agents

adverse effects

economics

pharmacology

therapeutic use

Antineoplastic Combined Chemotherapy Protocols

CTLA-4 Antigen

antagonists & inhibitors

Humans

Melanoma

drug therapy

economics

immunology

Mitogen-Activated Protein Kinase Kinases

antagonists & inhibitors

Oncolytic Virotherapy

Programmed Cell Death 1 Receptor

antagonists & inhibitors

Protein Kinase Inhibitors

adverse effects

economics

pharmacology

therapeutic use

Proto-Oncogene Proteins B-raf

antagonists & inhibitors

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)